Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection.
Davidorf
Frederick H
FH
Department of Ophthalmology, The Ohio State University, Columbus, Ohio 43210, USA.
Mouser
J Garret
JG
Derick
Robert J
RJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002830:Choroid Neoplasms / Q000473:pathology; D005451:Fluorescein Angiography; D015590:Fluorophotometry; D015355:Glaucoma, Neovascular / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D007498:Iris / Q000098:blood supply* / Q000473:pathology; D007499:Iris Diseases / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008545:Melanoma / Q000473:pathology; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab